Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Black Diamond Therapeutics Inc’s filing revealed that its 10% Owner Versant Venture Capital VI, L. unloaded Company’s shares for reported
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.